Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICE 1203
- Development stage
- Preclinical
- Lead developer
- iCeutica
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ICE 1203 is a preclinical-stage inhaled small molecule therapeutic being developed by iCeutica for the treatment of respiratory and allergic conditions, including asthma and chronic obstructive pulmonary disease (COPD). The candidate utilizes iCeutica's proprietary SoluMatrix fine particle technology, which employs a dry milling process to reduce drug particles to sub-micron sizes. This technology is intended to enhance the solubility and dissolution characteristics of the active pharmaceutical ingredient, potentially improving the efficacy and delivery profile of the inhaled medication compared to conventional formulations.
Beyond the preview
Go deeper on ICE 1203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICE 1203.